(MedPage Today) — At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients with diffuse large B-cell lymphoma…
Source link : https://www.medpagetoday.com/meetingcoverage/ashfuturefocusdlbcl/119036
Author :
Publish date : 2025-12-16 15:38:00
Copyright for syndicated content belongs to the linked Source.
